Abstract:First-line treatment for osteosarcoma includes chemotherapy and surgery. However, the five-year survival rate of refractory osteosarcoma remains unsatisfactory. Osteosarcoma cancer stem cells, possessing stemness and chemoresistance, are one of the critical causes of poor response to chemotherapy. Elucidating regulatory signaling pathways of osteosarcoma cancer stem cells may provide a rationale for improving regimens against chemoresistant osteosarcoma. Methotrexate (MTX)-resistant osteosarcoma cells were established. microRNA expression profiles were used for detecting differentially expressed microRNA in resistant clones and the parental cells. microRNA target databases were employed to predict potential microRNA and mRNA interactions. Flow cytometry was performed to measure stem cell marker Prominin-1 (CD133)-positive cells. Immunofluorescence staining was applied to detect CD133 expression. miR-197-3p mimic or anti-miR-197-3p stably transfected cells were used to generate xenograft models. In the study, we found that miR-197-3p was increased in MTX-resistant cell lines. Overexpression of miR-197-3p enhanced the expression of cancer stem cell markers CD133, Octamer-binding protein 4 (OCT4), Transcription factor SOX-2 (SOX2), and Homeobox protein NANOG (NANOG), as well as chemoresistance-associated genes ATP-dependent translocase ABCB1 (ABCB1) and Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2), whereas miR-197-3p knockdown inhibited stemness and recovered sensitivity to MTX. We also classified the tumor suppressor Speckle-type POZ protein-like (SPOPL) as a target of miR-197-3p. The miR-197-3p mutation that could not combine SPOPL promoter regions was unable to sustain stemness or chemoresistance. Collectively, we discovered miR-197-3p conferred osteosarcoma stemness and chemotherapy resistance by targeting SPOPL, prompting promising therapeutic candidates for refractory osteosarcoma treatment.

Thiostrepton and Mir-216B Synergistically Promote Osteosarcoma Cell Cytotoxicity and Apoptosis by Targeting FoxM1

microRNA-486 suppressed proliferation , migration and invasion of osteosarcoma cells via directly targeting SIRT 1

Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS

MicroRNA-455-3p Inhibits Osteosarcoma Progression Via HSF1 Downregulation

MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion Via Targeting IGF-1R

Microrna-370 Directly Targets Foxm1 to Inhibit Cell Growth and Metastasis in Osteosarcoma Cells

Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells

Combination Therapy with Bioengineered Mir-34A Prodrug and Doxorubicin Synergistically Suppresses Osteosarcoma Growth.

MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1.

Role of FOXM1 Expression Inbibition Regulated by Thiostrepton in the Proliferation and Apoptosis of Lung Cancer Cells

Tumor-Suppressing Effects of Mir-429 on Human Osteosarcoma

MicroRNA-212 Suppresses the Proliferation and Migration of Osteosarcoma Cells by Targeting Forkhead Box Protein A1

Tumor-Suppressing Effects of miR451 in Human Osteosarcoma

Inhibiting Proliferation and Enhancing Chemosensitivity to Taxanes in Osteosarcoma Cells by RNA Interference-Mediated Downregulation of Stathmin Expression

miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL

MicroRNA-143 Promotes Apoptosis of Osteosarcoma Cells by Caspase-3 Activation Via Targeting Bcl-2.

MiR-138 Acts As a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells

MicroRNA-377 exerts a potent suppressive role in osteosarcoma through the involvement of the histone acetyltransferase 1-mediated Wnt axis

Inhibition of FOXM1 by Thiostrepton Sensitizes Medulloblastoma to the Effects of Chemotherapy.

Mir-16-5p Suppresses Progression and Invasion of Osteosarcoma Via Targeting at Smad3

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma